ConforMIS (NASDAQ: CFMS) and COLOPLAST A/S/ADR (OTCMKTS:CLPBY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.
Volatility and Risk
ConforMIS has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, COLOPLAST A/S/ADR has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.
Insider & Institutional Ownership
44.1% of ConforMIS shares are owned by institutional investors. Comparatively, 0.1% of COLOPLAST A/S/ADR shares are owned by institutional investors. 7.6% of ConforMIS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares ConforMIS and COLOPLAST A/S/ADR’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares ConforMIS and COLOPLAST A/S/ADR’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ConforMIS||$78.11 million||0.94||-$53.58 million||($1.24)||-0.98|
|COLOPLAST A/S/ADR||$2.31 billion||8.39||$564.23 million||$0.27||36.22|
COLOPLAST A/S/ADR has higher revenue and earnings than ConforMIS. ConforMIS is trading at a lower price-to-earnings ratio than COLOPLAST A/S/ADR, indicating that it is currently the more affordable of the two stocks.
COLOPLAST A/S/ADR pays an annual dividend of $0.10 per share and has a dividend yield of 1.0%. ConforMIS does not pay a dividend. COLOPLAST A/S/ADR pays out 37.0% of its earnings in the form of a dividend.
This is a summary of recent ratings and recommmendations for ConforMIS and COLOPLAST A/S/ADR, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ConforMIS presently has a consensus target price of $4.00, suggesting a potential upside of 230.58%. Given ConforMIS’s higher probable upside, equities analysts clearly believe ConforMIS is more favorable than COLOPLAST A/S/ADR.
COLOPLAST A/S/ADR beats ConforMIS on 9 of the 15 factors compared between the two stocks.
ConforMIS, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides ConforMIS Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, and Monaco. ConforMIS, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts.
About COLOPLAST A/S/ADR
Coloplast A/S develops and markets intimate healthcare products and services worldwide. The company operates through three segments: Chronic Care, Urology Care, and Wound & Skin Care. It provides ostomy care products for intestinal dysfunction resulting from disease, accident, and congenital disorder. The company's ostomy care products include colostomy, ileostomy, and urostomy bags under the SenSura brand; and SenSura Mio, a colostomy product with elastic adhesive that fits individual body shapes, as well as ostomy accessories under the Brava brand. It also offers urology care products for people suffering from diseases and symptoms of the urinary system, pelvic floor prolapse, and the male reproductive system, such as urinary incontinence, kidney stones, enlarged prostate, and impotence. The company's disposable surgical devices include prostate catheters and stents used for urological and gynecological applications before, during, and after surgery under the Porgès brand; vaginal slings to restore continence; synthetic mesh products to treat weak pelvic floor; and penile implants for men. In addition, it provides continence care products, such as SpeediCath catheters that offer catherisation for both genders; Peristeen, an anal irrigation system for controlled emptying of the bowels; and Conveen Active urine bags. Further, the company offers wound care products, such as foam dressings under the Biatain brand and hydrocolloid dressing under the Comfeel brand, as well as skin care products, such as disinfectant liquids or creams used to protect and treat the skin and to clean wounds. Additionally, it offers Interdry, a textile placed in a skin fold to absorb moisture for treatment and prevention of skin fold problems, such as fungal infections, damaged skin, or odour nuisance. The company supplies its products to hospitals, institutions, wholesalers, and pharmacies; and directly to users. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.
Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.